| Semaglutide |
 |
| C187H291N45O59 |
 |
| 910463-68-2 |
 |
Semaglutide is a glucagon-like peptide-1 receptor agonist used in individuals with type 2 diabetes as an addition to diet and exercise to improve glycemic control.Semaglutide is a GLP-1 mimic having 94% sequence homology to human GLP-1.It can bind to the GLP-1 receptor and activate the receptor to lower blood sugar by boosting insulin production and decreasing glucagon secretion as a GLP-1 receptor agonist.Furthermore,semaglutide can act on the digestive tract by delaying gastrointestinal emptying to induce fullness
on the brain by suppressing appetite
and on the circulatory system by repairing damaged intima and improving endothelial function.
Benefits:
Semaglutide is a versatile medication that offers a range of benefits for individuals with various medical conditions.Some of the most common conditions that can benefit from the use of AASraw Semaglutide including Type 2 Diabetes Mellitus,caidiovascular risks,obesity and Alzheimer.
¨çLowering Blood Glucose Levels
Semaglutide is a GLP-1 receptor agonist that is effective in lowering blood glucose levels in people with type 2 diabetes by several mechanisms.It stimulates insulin secretion,which helps to move glucose from the blood into the cells where it can be used for energy.Semaglutide also suppresses glucagon secretion,which reduces glucose production by the liver.Additionally,it slows down gastric emptying,which reduces the rate at which glucose enters the bloodstream after a meal.
In clinical trials,semaglutide has been shown to significantly reduce HbA1c levels,which is an indicator of long-term blood glucose control.In the SUSTAIN-1 trial,semaglutide reduced HbA1c levels by 1.5% compared to placebo,and in the SUSTAIN-10 trial,it reduced HbA1c levels by 1.8% compared to placebo.Semaglutide has also been shown to be effective in reducing fasting plasma glucose levels and postprandial glucose excursions.
¨èReducing Risk of Cardiovascular Events
Semaglutide has been shown to reduce the risk of major adverse cardiovascular events (MACE) such as cardiovascular death,nonfatal myocardial infarction,and nonfatal stroke in adults with type 2 diabetes and established cardiovascular disease.This benefit was observed in the SUSTAIN-6 and PIONEER-6 trials,which showed a significant reduction in MACE with semaglutide treatment compared to placebo.Moreover,Semaglutide has been shown to improve several cardiovascular risk factors such as blood pressure,lipid profile,and markers of inflammation in people with type 2 diabetes.In the SUSTAIN-6 trial,semaglutide was associated with a significant reduction in systolic blood pressure and improvement in lipid profile,including reductions in total cholesterol,LDL cholesterol,and triglycerides.
¨éLosing Weight
Semaglutide is a potent weight loss agent,even in people without diabetes.Semaglutide works by reducing appetite and calorie intake,leading to a decrease in body weight.This is achieved through its effects on the central nervous system and the gastrointestinal tract.Semaglutide acts on the hypothalamus,which regulates hunger and satiety,and reduces the desire to eat by increasing feelings of fullness.Additionally,semaglutide slows down gastric emptying,which prolongs the feeling of fullness after a meal and reduces the urge to eat.
Clinical trials have demonstrated the weight loss benefits of semaglutide.In the STEP program,which evaluated the use of semaglutide for weight management in people without diabetes,semaglutide was associated with significant weight loss compared to placebo.Participants who received once-weekly semaglutide lost an average of 15% of their body weight over 68 weeks,while those who received placebo lost only 2.4%.
In people with type 2 diabetes,semaglutide can lead to additional weight loss benefits.In the SUSTAIN 7 trial,which evaluated the efficacy and safety of semaglutide in people with type 2 diabetes,semaglutide was associated with a significant reduction in body weight compared to placebo.Participants who received semaglutide lost an average of 4.6 kg,while those who received placebo lost only 1.2 kg.
¨êTreating Alzheimer¡¯s Disease Symptom
Multiple preclinical studies have shown that semaglutide has neuroprotective properties against amyloid-¥â plaques in a human neuroblastoma (SH-SY5Y) cell line,suggesting that semaglutide can alleviate Alzheimer¡¯s disease symptom.Animal models have also shown that semaglutide has neuroprotective effects on animal models.According to Novo Nordisk¡¯s announcement,the indication of semaglutide tablets for Alzheimer¡¯s disease (AD) is in the clinical stage.Two global Phase III trials,EVOKE and EVOKE plus,are underway,and about 3,700 volunteers are expected to be recruited.In this study,compared with placebo,evaluate the superiority of semaglutide tablets on cognitive function in subjects with mild cognitive impairment (MCI) or mild dementia caused by AD. |
 |
medical use
|
 |
Molecular Weight:4113.58g/mol
Melt Point: 34-39¡ÆC
Color: White
|
| Industrial field |
pharmaceutical |
|
|
 |
 |
|
AASraw/Aea.ltd
|
| Phone |
+13204026693 |
| Fax |
|
| Homepage |
- |
| E-mail |
King@aea.ltd
|
| Address |
FLAT/RM C1 4/F SUMMIT BUILDING 30 MAN YUE STREET HUNG HOM,HONG KONG,CHINA |
|
 |
|
|
|
|
 |
| There are no existing companies to distribute selected chemical product |
|
|
|
|
